{
  "@context": "aku-v2",
  "@type": "definition",
  "@id": "vascular:pad:in-stent-restenosis:definition",
  "metadata": {
    "version": "1.0.0",
    "created": "2026-01-05T17:43:00.000Z",
    "contributors": ["copilot"],
    "status": "validated",
    "confidence": 0.92
  },
  "classification": {
    "domain_path": "health-sciences/medicine/surgery/vascular/pad",
    "type": "definition",
    "difficulty": "intermediate",
    "importance": "clinical",
    "board_yield": "HIGH"
  },
  "content": {
    "term": "In-Stent Restenosis",
    "synonyms": ["ISR", "Neointimal Hyperplasia", "Stent Failure"],
    "definition": "The development of significant luminal narrowing within a previously placed arterial stent, most commonly due to neointimal hyperplasia. In-stent restenosis is a major limitation of endovascular therapy, particularly in the femoropopliteal segment.",
    "pathophysiology": {
      "mechanism": [
        "Vascular injury from stent placement",
        "Inflammatory response",
        "Smooth muscle cell migration and proliferation",
        "Extracellular matrix deposition",
        "Neointimal hyperplasia formation"
      ],
      "timeline": [
        "Begins immediately after stent placement",
        "Clinically significant at 6-24 months",
        "May continue to progress"
      ],
      "contributing_factors": [
        "Stent fracture",
        "Stent underexpansion",
        "Geographic miss (disease at stent edges)",
        "Small vessel diameter",
        "Diabetes",
        "Continued smoking"
      ]
    },
    "clinical_presentation": [
      "Recurrence of claudication symptoms",
      "Return of rest pain or tissue loss",
      "Worsening ABIs",
      "May be asymptomatic (detected on surveillance)"
    ],
    "classification": {
      "tosaka_classification": [
        "Class I: Focal ISR (<50 mm)",
        "Class II: Diffuse ISR (>50 mm)",
        "Class III: Total occlusion"
      ],
      "significance": ">50% stenosis with hemodynamic significance or symptoms"
    },
    "location_specific_rates": {
      "iliac": "10-20% at 1 year",
      "femoropopliteal_bare_metal": "30-50% at 1 year",
      "femoropopliteal_drug_coated": "15-25% at 1 year",
      "infrapopliteal": "40-60% at 1 year"
    },
    "prevention": {
      "drug_coated_technology": [
        "Drug-coated balloons (DCB)",
        "Drug-eluting stents (DES)",
        "Paclitaxel most studied drug"
      ],
      "technical_factors": [
        "Proper sizing (avoid undersizing)",
        "Adequate lesion preparation",
        "Avoid stent fracture zones (across joints)"
      ],
      "medical_therapy": [
        "Antiplatelet therapy",
        "Statin therapy",
        "Smoking cessation"
      ]
    },
    "treatment": {
      "drug_coated_balloon": [
        "First-line for ISR treatment",
        "Better outcomes than plain balloon",
        "Avoid adding more metal (stent in stent)"
      ],
      "atherectomy_plus_dcb": [
        "Debulk neointimal tissue",
        "Follow with DCB",
        "May improve durability"
      ],
      "surgical_bypass": [
        "For extensive ISR not amenable to endovascular",
        "Or after multiple endovascular failures"
      ]
    },
    "surveillance": {
      "recommended": "Duplex ultrasound at 1, 6, 12 months, then annually",
      "criteria_for_intervention": [
        ">50% stenosis with symptoms",
        "PSV ratio >2.5",
        "Declining ABI"
      ]
    }
  },
  "codes": {
    "snomed_ct": "301712004",
    "icd_10": "T82.855A"
  },
  "relationships": {
    "broader": ["vascular:pad:endovascular-complications"],
    "related": ["vascular:pad:stenting", "vascular:dcb:femoropopliteal"],
    "narrower": []
  },
  "pedagogical": {
    "learning_objectives": [
      "Understand pathophysiology of neointimal hyperplasia",
      "Know Tosaka classification of ISR",
      "Know treatment options for ISR"
    ],
    "clinical_pearls": [
      "Femoropopliteal ISR occurs in 30-50% with bare metal stents at 1 year",
      "Neointimal hyperplasia is the dominant mechanism",
      "Drug-coated balloons are FIRST-LINE for ISR treatment",
      "Avoid stent-in-stent when possible - adds more metal",
      "Tosaka I (focal) has better outcomes than Tosaka III (occlusion)",
      "Surveillance essential: duplex at 1, 6, 12 months"
    ]
  }
}
